請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28087
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳信銘 | |
dc.contributor.author | Ming-Fan Tsai | en |
dc.contributor.author | 蔡旻汎 | zh_TW |
dc.date.accessioned | 2021-06-13T00:00:54Z | - |
dc.date.available | 2008-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-31 | |
dc.identifier.citation | 文獻參考
行政院衛生署:中華民國九十二年衛生統計。 行政院衛生署:中華民國九十二年癌症登記報告。 國家衛生研究院:檳榔嚼塊與口腔癌流行病學研究。民國九十年。 黃湧澧, 林立民, 葛應欽 : 檳榔塊與口腔癌. 公共衛生雜誌. 1993; 19: 371-383. 黃志浩, 謝天渝: 轉型生長因子-在口腔黏膜下纖維化病變之免疫組織化學表現. 台灣口腔醫誌 1999; 15:227-239. 嚼檳榔引發之口腔黏膜纖維化症:流行病學與致病機轉 出版年月: 2001-08: 1-3頁 黃顯成:高雄醫學院口腔組織病理標本分析研究(1985-1996)──含口腔癌病患之存活率及放射線影像相關分析。 蔡崇弘及邱清華:臺灣地區口腔癌發生率研究。中華牙誌,九卷三期,第104-115 頁,民國七十九年 陳金勝和陳中和:口腔鱗狀上皮細胞癌之統計分析報告,Kaohsiung JMed Sci 1995; 11: 582-588。 Ballestar E, Esteller M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 2002; 23: 1103-9. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantu D, Gonzalez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E, Duenas-Gonzalez A. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005 Jul 7;4(1):22. Chen CH: An epidemiological study of oral squamous cell carcinoma in Southern Taiwan. J Formosan Dent Assoc 1987; 10: 268-274. Chiba I. Prevention of BQ Chewers’Oral Cancer in the Asian-Pacific Area Asian Pacific. J Cancer Prev 2001; 2: 263–9. Chiu CJ, Lee WC, Chiang CP, Hahn LJ, Kuo YS, Chen CJ. A scoring system for the early detection of oral submucous fibrosis based on a self-administered questionnaire. J Public Health Dent 2002; 62: 28-31 Clayman GL, Lippman SM, Laramore GE, Hong WK. Head and neck cancer. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum R (ed). Cancer Medicine, pp. 1645-1709, Philadelphia: Williams and Wilkins, 1996. Cox SC, Walker DM. Establishing a normal range for mouth opening: its use in screening for oral submucous fibrosis. Br J Oral Maxillofac Surg. 1997;35:40-2. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004 Apr 12;23(16):2950-66. Review. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005 Oct 1;96:293-304. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002 Aug12;21(35):5427-40. Review. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005 Apr;37(4):391-400. Fulda S, Debatin KM. Signaling through death receptors in cancer therapy. Curr Opin Pharmacol. 2004; 4(4):327-32. Review. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005 Dec 19;363:15-23 Gruss HJ: Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clini Lab Res 1996; 26: 143. review. Grutter MG. Caspases: key players in programmed cell death. Curr Opin Struct Biol 2000;10:649-655. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241-6. Gupta PC, Metha FS, Daftary DK, et al.: Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-years follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980; 8:287-333. Gupta D, Sharma SC. Oral submucous fibrosis-a new treatment regimen. J Oral Maxillofac Surg 1988;46:830-3. Gupta PC, Sinor PN, Bhonsle RB, Pawar VS, Mehta HC. Oral submucous fibrosis in India: a new epidermic. Natl Med J India 1998;11:113–6. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis. 2004 Nov;9(6):691-704. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.Prostate. 2004;59(2):177-89. Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol. 2004 Mar;45(3):382-9 Harada H, Grant S. Apoptosis regulators. Rev Clin Exp Hematol. 2003 Jun;7(2):117-38. Review. Hanahan D and Weinberg RA. The Hallmarks of Cancer. Cell, Vol. 100,2000. 57–70, January 7, 2000. Heiser D, Labi V, Erlacher M, Villunger A. The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol. 2004 Aug;39(8):1125-35. Review. Hsu CH, Chang MD, Tai KY, Yang YT, Wang PS, Chen CJ, Wang YH, Lee SC, Wu CW, Juan LJ. HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. EMBO J. 2004 2;23(11):2269-80. International Agency for Research on Cancer. Betel-quid and areca nut chewing and some areca nut derived nitrosoamines, vol. 85. Lyon: IARC; 2004. p. 123–9. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005 Jan;11(1):71-6. Iizuka M, Smith MM. Functional consequences of histone modifications. Curr Opin Genet Dev 2003; 13: 154-60. Jenuwein, T. and Allis, C.D. 2001. Translating the histone code. Science 293: 1074-1080. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-99. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002 Jun;3(6):415-28. Review. Kazuhiro Ito, Ph.D., Misako Ito, B.A., W. Mark Elliott, Ph.D., Borja Cosio, M.D.,Gaetano Caramori, Ph.D., Onn Min Kon, M.D., Adam Barczyk, M.D.,Shizu Hayashi, Ph.D., Ian M. Adcock, Ph.D., James C. Hogg, M.D., and Peter J. Barnes, D.M., D.Sc.: Decreased Histone Deacetylase Activity in Chronic Obstructive Pulmonary Disease N Engl J Med 2005;352:1967-76. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol. 2002 May;14(3):334-42. Review. Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol. 2002;50(5):343-52. Review. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005 Mar;90(1):15-23. Kuo MYP, Chen HM, Hahn LJ, Hsieh CC, Chiang CP. Collagen biosynthesis in human oral submucous fibrosis fibroblast cultures. J Dent Res 1995;74:1783–8. Kwan HW: A statistical study on oral carcinomas in Taiwan with emphasis on the relationship with betel nut chewing: a preliminary report. J Formosan Med Assoc 1976; 75: 497-505 Lal D. Diffuse oral submucous fibrosis. J All-India Dent Assoc 1953; 26:1-3. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001 Apr;7(4):383-5. Lin SC, Chang KW, Chang CS, Liu TY, Tzeng YS, Yang FS, Wong YK. Alterations of p16/MTS1 gene in oral squamous cell carcinomas from Taiwanese. J Oral Pathol Med. 2000; 29:159-66. Littau VC, Burdick CJ, Allfrey VG, Mirsky SA. The role of histones in the maintenance of chromatin structure. Proc Natl Acad Sci USA 1965; 54: 1204–1212. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000 Mar;21(3):485-95. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004 Apr 15;64(8):2840-5. Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD 2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 2001;98:4990-4995. Maher R, Lee AJ, Warnakulasuriya KAAS, Lewis JA, Johnson NW. Role of areca nut in the causation of oral submucous fibrosis: a case-control study in Pakistan. J Oral Pathol Med 1994;23:65-9. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev. 2005;25(3):261-309. Review. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies.Nat Rev Cancer. 2001 Dec;1(3):194-202. Review. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/ MTS1 in human cancers. Nat Med. 1995;1(7):686-92. Meghji S, Scutt A, Canniff JP, Harvey W, Phillipson JD.Inhibition of collagenase activity by areca nut tannins: a mechanism of collagen accumulation in oral submucous fibrosis J Dent Res 1982;61:545. Meghji S, Scutt A, Harvey W, Canniff JP. An in vitro comparison of human fibroblasts from normal and oral submucous fibrosis tissue. Arch Oral Biol 1987;32:213–5. Murti PR, Bhonsle RB, Gupta PC et al.: Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing. J Oral Pathol Med 1995;24:145-52. Nakagawa T,Zhu H,Morishima N,et al.Caspase-12 mediates endoplasmic-reticulum -specific apoptosis and cytotoxicity by amyloid-beta. Nature,2000,403(2):98-10 3. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med. 2005;11(1):77-84. Niki T, Rombouts K, De Bleser P, DeSmet K,Rogiers V, Schuppan D,Yoshida M, Gabbiani G, Geerts A:A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellat cells in primary culture.Hepatology 29:858-867,1999 Niko Klan1, Sabine Seuter1, Nicole Schnur1,Manfred Jung2 and Dieter Steinhilber1, Trichostatin A and Structurally Related Histone Deacetylase Inhibitors Induce 5-Lipoxygenase Promoter Activity Biol. Chem., 384, 777 – 785, 2003 Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87: 953–959. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003;63(15):4460-71. Pindborg JJ, Mehta FS, Gupta PC, Daftary DK. Prevalence of oral submucous fibrosis among 50,915 Indian villagers. Br J Cancer 1968;22:646-54. Pindborg JJ: Is submucous fibrosis a precancerous condition in the oral cavity Int Dent J 1972;22:474-80. Pindborg JJ. Oral cancer and precancer. Bristol: John Wright, 1980: 108-11. Pindborg JJ, Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Mehta FS: Oral submucous fibrosis as a precancerous condition. Scand J Dent Res 1984 ;92:224-9. Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol. 2004 Jun;26(2):82-97. Review. P.J. Barnes, I.M. Adcock and K. Ito:Histone acetylation and deactylation ;importance in inflammatory lung diseases Eur Respir J 25:552 563, 2005 Review. P. Rajalalitha, S. Vali: Molecular pathogenesis of oral submucous fibrosis –a collagen metabolic disorder J Oral Pathol Med (2005) 34: 321–8 Ranganathan K, Uma Devi M, Joshua E, Kirankumar K, Saraswathi TR. Oral submucous fibrosis: a case control study in Chennai South India. J Oral Pathol Med 2004;33:274–7. Rombouts K,Niki T,Greenwel P, Vandermonde A, Wielant A, Hellemans K, De Bleser P Yoshida M, Schuppan D,Rojkind M,Geerts A:Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevent TGF-beta1-induced fibrogenesis in skin fibroblasts.Exp Cell Res 278:184-197,2002 Rishikof DC,Recuparo DA, Liu H, Goldstein RH:Phenylbutyrate dcreases type I collagen production in human lung fibroblasts. J Cell Biochem91:740-748,2004 Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81–120. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004;46(2):171-8. Seedat HA. Oral submucous fibrosis in Durban, Natal: a study of its epidemiology, aetiology and morphological features. Thesis. Stellenbosch, South Africa. University of Stellenbosch, 1985. Seedat HA, Van Wyk CW. Submucous fibrosis in non-betel nut chewing subjects. J Biol Buccale 1988;16:3–6. Seedat HA, Van Wyk CW. Betel nut chewing and oral submucous fibrosis in Durban. S Afr Med J 1988;74:572–5. Sinor PN, Gupta PC, Murti PR, Bhonsle RB, Daftary DK, Mehta FS, Pindborg JJ. A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med 1990;19:94-8. Sirsat SM, Pindborg JJ: Subepithelial changes in oral submucous fibrosis. Acta Pathol Microbiol Scand 1967;70:161-73. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005; 113: 264-8. Sprick MR, Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta. 2004 Mar 1;1644(2-3):125-32. Review. Shah N, Sharma PP. Role of chewing and smoking habits in the etiology of oral submucous fibrosis (OSF): a case-control study. J Oral Pathol Med 1998;27:475-9. Shiau YY, Kwan HW: Submucous fibrosis in Taiwan. Oral Surg 1979; 47: 453-7. Thompson, C.B. (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462,1995 Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, Yonemasu H, Hachitanda Y, Okamura T, Sugimachi K. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep. 2003 Mar-Apr;10(2):333-8. Tang JG, Jian XF, Gao ML, Ling TY, Zhang KH. Epidemiological survey of oral submucous fibrosis in Xiangtan City, Hunan province, China. Community Dent Oral Epidemiol 1997;25:177-80. Utsunomiya H, Tilakaratne WM, Oshiro K, Maruyama S, Suzuki M, Ida-Yonemochi M, et al. Extracellular matrix remodeling in oral submucous fibrosis; its stage-specific modes revealed by immuno-histochemistry and in-situ hybridization. J Oral Pathol Med 2005;34:498–507. Villar-Garea A, Esteller M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr Drug Metab 2003; 4: 11-31. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer. 2004 Nov 1;112(2):171-8. Review. Wang CY, Lin JK, Chen BF, Chiang HK. Autofluorescence spectroscopic differentia tion between normal and cancerous colorectal tissues by means of a two-peak ratio algorithm. J Formos Med Assoc 1999; 98: 837-43. Warnakulasuriya S. Semi-quantitative clinical description of oral submucous fibrosis. Ann Dent 1987; 46: 18-21. Warnakulasuriya S. Clinical and pathological criteria for diagnosis of oral submucous fibrosis. In: Procedings of the First Asia-Pacific Workshop for Oral Mucosal Lesions. Nagoya: Japan, 1992. W.M. Tilakaratne , M.F. Klinikowski , Takashi Saku ,T.J. Peters , Saman Warnakulasuriya , :Oral submucous fibrosis: Review on aetiology and pathogenesis Oral Oncology 2005 635 8-6 Youngqing Wang, Pan-Sheng Fan, and Bashar Kahaleh: Association Between Enhanced Type I Collagen Expression and Epigenetic Repression of the FLI1 Gene in Scleroderma Fibroblasts. ARTHRITIS & RHEUMATISM . 54,2271–2279 2006 Zain RB, Ikeda N, Razak IA, et al. A national epidemiological survey of oral mucosal lesions in Malaysia.Community Dent Oral Epidemiol 1997; 25: 377–83. Zain RB, Ikeda N, Gupta PC, et al. Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, 1996. J Oral Pathol Med 1999; 28: 1–4. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004 May;5(5):455-63. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28087 | - |
dc.description.abstract | 中文摘要
口腔黏膜下纖維化症(oral submucous fibrosis :OSF)是因嚼食檳榔而使口腔黏膜下結締組織產生過度纖維化的癌前狀態。在於許多器官如:肝、肺、皮膚…等的過度纖維化疾病,經研究發現都有過度的HDAC-2之表現。因此,將探討HDAC-2與OSF纖維化致病機轉的關聯性。首先本研究我們先分別收集了59例OSF病患與15例正常人的口腔頰黏膜組織標本,利用HDAC-2抗體進行免疫組織化學染色方法,偵測HDAC-2在這些標本之染色表現,結果發現15例正常組織其HDAC-2免疫染色呈現無或微弱之表現(發生率ICR=13.3%),而59例OSF組織則呈陽性反應(發生率ICR=96.6%),顯示OSF組織比正常者的HDAC-2有過度表現,且具統計學上差異的顯著(P=0.0045)。其次本研究使用OSF以及正常者口腔頰黏膜組織所培養出的纖維母細胞,抽取其蛋白質,以西方點墨法了解HDAC-2的表現,並利用抑制HDAC-2表現的藥物SAHA (suberoylanilide hydroxamic acid),在不同的時間點,分別作用在OSF以及正常者的口腔纖維母細胞,結果發現OSF fibroblasts HDAC-2的表現比正常者有過度的表現(P<0.05)。在加入SAHA作用後,雖然OSF與正常者纖維母細胞的HDAC-2表現皆被抑制,然而在SAHA作用12小時後,正常者的纖維母細胞HDAC-2被抑制的程度比OSF者高,且有顯著的差異(P<0.05)。換言之,OSF纖維母細胞比正常者有更高HDAC-2的表現且不易被HDAC-2的抑制劑所抑制。因此,本研究結果發現,膠原蛋白的過度堆積與HDAC-2的過度表現及不易被其抑制劑抑制有關。 | zh_TW |
dc.description.abstract | ABSTRACT
Oral submucous fibrosis (OSF) is a chronic debilitating disease and a pre-malignant condition of the oral cavity. It is characterized by a generalized submucous fibrosis. Epidemiological evidences strongly indicate the association of the areca quid (AQ) habit and OSF. It is regarded as a pre-cancerous condition. HDAC-2 (Histone deacetylase H2) has been evidenced to have over expression in some organs, such as lung, liver, and skin, but the underlying mechanisms remain to be clarified. In our study, we will discuss the pathogenesis between the severity of Oral submucous fibrosis (OSF) and the expression of HDAC-2 (Histone deacetylase H2). In the beginning, we collect 59 OSF specimens and 15 normal buccal mucosa that were examined the expression of HDAC-2 by immunohistochemistry (IHC). All patients received surgical excision of their precancerous at the Department of Oral and Maxillofacial Surgery, National Taiwan University Hospital, Taipei, Taiwan. The results of this study showed the HDAC-2 positive rate of OSF is significantly higher than that of normal oral mucosa (NOM) (P=0.0045).The incident rate of the OSF(ICR=96.6%)specimens, HDAC-2 is strongly expressed in the fibroblasts of connective tissue more than normal buccalmucosa(ICR=13.3%)specimens. In addition, the expression of HDAC-2 protein between OSF and NOM was quantified with the use of Western blotting and the results showed the same with IHC assay. Besides, SAHA (suberoylanilide hydroxamic acid) an HDAC-2 inhibitor was added to find the effect on OSF and NOM in a time- dependent manner by western blotting assay. And our studied indicated that after we added the SAHA for 12 hours this inhibitor is markedly reduced the expression of HDAC-2, especially in OSF (p<0.05). In other word, we can see the result suggests that In the OSF , HDAC-2 is strongly expressed in the fibroblasts of connective tissue protein more than normal buccal mucosa. And the result finds that HDAC-2 is higher expression and harder to be repressed in the OSF than in the NOM. Hence, the result suggests that over deposition of collagen maybe related to the over expression and hard to be repressed of HDAC-2 in the OSF. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T00:00:54Z (GMT). No. of bitstreams: 1 ntu-96-R94450018-1.pdf: 1780566 bytes, checksum: cf2025945d9ccdf983eae0617586f9bd (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 謝誌……………………………………………………………………Ⅰ
中文摘要………………………………………………………………Ⅱ Abstract…………………………………………………………Ⅲ 第一章 研究動機及目的……………………………………………1 第二章 口腔黏膜下纖維化症致病機轉的研究……………………4 一、前言 …………………………………………………………4 二、文獻回顧……………………………………………………5 第三章、實驗材料及方法……………………………………………10 3-1. 實驗組與控制組檢體的收集………………………………10 3-2.臨床資料的收集……………………………………………10 3-3.免疫組織化學染色(immunohistochemical stain)方法標本的固定和包埋………………………………………………10 3-4.陽性染色率判斷標準………………………………………14 3-5.統計方法……………………………………………………14 3-6.類頰黏膜纖維母細胞之培養………………………………14 3-7.繼代培養Subculture --(以10 cm培養皿為例)…………15 3-8.Counting and seeding………………………………………15 3-9. Cryopreservation --- Freezing cells………………15 3-10. Treatments ………………………………………………16 3-11.細胞毒性試驗………………………………………………16 3-12.西方點墨法 (Western Blotting Assay)…………………16 3-13統計分析 (statistical analysis)……………………19 第四章、結果…………………………………………………………20 4-1 免疫組織染色IHC結果……………………………………20 4-2 OSF之病歷資料與HDAC-2相關結果統計分析…………20 4-3 MTT測量結果………………………………………………21 4-4 SAHA藥物對抑制人類纖維母細胞與HDAC-2之相關 影響…………………………………………………………22 4-5 Collagen type I 與FLI-1在加入抑制HDAC-2藥物SAHA後之表現…………………………………………………………23 第五章、討論………………………………………………………24 第六章、總結………………………………………………………28 第七章、附表與附圖…………………………………………………30 參考文獻………………………………………………………………54 | |
dc.language.iso | zh-TW | |
dc.title | 口腔黏膜下纖維化症中HDAC-2表現及可能致病機轉之研究 | zh_TW |
dc.title | HDAC-2 expression in oral submucous fibrosis and its possible pathogenesis and mechanism | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 郭彥彬 | |
dc.contributor.oralexamcommittee | 江俊斌,張龍昌 | |
dc.subject.keyword | 口腔黏膜下纖維化症,第一型膠原蛋白,組蛋白去乙醯化, | zh_TW |
dc.subject.keyword | oral submucous fibrosis,HDAC-2,collagen typeI, | en |
dc.relation.page | 61 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 1.74 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。